Diagnostics and management of direct oral anticoagulants-induced bleeding
Review published in Current opinion in anaesthesiology (2025)
Abstract
PURPOSE OF REVIEW: To provide evidence-based management of patients on direct oral anticoagulants (DOAC) needing acute procedures, including those facing hemorrhage. RECENT FINDINGS: Standard coagulation parameters are insufficient for precise DOAC plasma level measurement; calibrated anti factor X activated assays are reliable, and point-of-care assays may be useful in urgent situations. For intracerebral hemorrhage (ICH) in patients on DOACs, direct reversal strategies seem to be more effective than nonspecific hemostatic agents, but evidence still remains unclear in terms of efficacy and safety compared to nonspecific hemostatic agents. Before invasive procedures like neuraxial anesthesia or cerebral thrombectomy, idarucizumab is recommended for dabigatran-treated patients, despite recent observational data not fully supporting this. No recommendations can be made for FXa inhibitors because of the lack of data. SUMMARY: Clinicians should assess the overall risk of bleeding for an acute procedure or the severity of any ongoing hemorrhage in DOAC-treated patients before initiating any reversal treatment, regardless of current evidence levels.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
To provide evidence-based management of patients on direct oral anticoagulants (DOAC) needing acute procedures, including those facing hemorrhage.
Why This Matters for Hirudotherapy
This review summarizes evidence-based management of patients on direct oral anticoagulants (DOACs) who need acute procedures or are bleeding, concluding that standard coagulation tests are insufficient for precise DOAC levels while calibrated anti-FXa assays are reliable, that direct reversal appears more effective than nonspecific hemostatic agents for intracerebral hemorrhage though the comparative evidence remains unclear, and that idarucizumab is recommended before urgent procedures in dabigatran-treated patients (with no firm recommendation possible for FXa inhibitors). Its ASH relevance is via dabigatran, an oral direct thrombin inhibitor whose mechanism descends from the hirudin-class thrombin-inhibition concept rooted in leech research, so the piece informs how clinicians monitor and reverse this DTI lineage. Caveat: as a narrative review it aggregates and interprets others' findings rather than generating new data, the authors themselves note evidence gaps and unclear efficacy/safety, and the medicinal-leech link is conceptual—dabigatran is a synthetic small molecule, not a leech-derived agent.
Citation
Diagnostics and management of direct oral anticoagulants-induced bleeding
von Heymann C et al. · Current opinion in anaesthesiology, 2025
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026